Saby George, MD, FACP, Associate Professor of Medicine and Oncology, Genitourinary Oncology Program , Roswell Park Cancer Institute presents
Nivolumab as a second-line therapy for metastatic RCC at the 2016 annual International Kidney Cancer Symposium.
Nivolumab as a second-line therapy for metastatic RCC
